6 TECH OUTLOOKFebruary - 2020EditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comAccording to recent studies, the major factors found propelling the growth of the clinical research market include the high demand for clinical trials in emerging markets, increased R&D spending of the pharmaceutical industry, and an increasing prevalence of diseases, with focus on rare diseases and multiple orphan drugs in the pipeline. The clinical trial market is growing at a robust pace, owing to the advancements in healthcare and growing patented new chemical entities (NCE) indicated for various health conditions. The costs of drug development has shot up in the past decade, forcing pharmaceutical companies to look for innovations and smarter ways of doing business. One of the major in trends that have resulted from high costs is companies outsourcing their clinical research activities. By outsourcing their R&D functions, pharmaceutical companies are reshaping the drug development services industry. These service providers have grown from just a few companies providing limited clinical trial services to big multinationals offering a wide range of services like preclinical evaluations, study design, clinical trial planning and management, independent safety data monitoring, bio-statistical analysts and many more. CROs already provided preclinical and clinical trial services, but they are now expanding into project management. Sponsor networking and regulatory consulting.Owing to the growing number of unmet clinical needs in emerging countries due to the prevalence of infectious and tropical diseases in the region, a large number of the population is expected to participate in clinical trials to access high-quality healthcare free of cost. India and China could be the most anticipated markets as both the nations have the highest prevalence rates for metabolic disorders, due to the increasing population, combined with the prevalence of insulin resistance, hyperlipidemia, and obesity. In addition, government initiatives have also motivated the small, medium, and large players to enter into orphan drug development. Thus, there are multiple drugs in the pipeline. It has also been found that the clinical trials market has taken bigger strides in the developing countries of Asia-Pacific and the Middle East and there is still very less development in the market. This edition brings you some of the most prominent companies that specialize in clinical trial landscape and have excelled with their service and will be major drivers of the aforementioned trends to mainstream.Let us know your thoughts!The future of Clinical R&DCopyright © 2020 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.FEBRUARY - 10 - 2020, Vol 06 - Issue 01 (ISSN 2644-2787) Published by ValleyMedia Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerAsher BlakeEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Contact Us:Phone:510.556.2402, Fax:510-894-8405Ronald DonovanTECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >